微信直播

Prof. Yuji Heike:免疫治疗之路道阻且

Published at: 2015年第1卷第S1期

李肖梅
关键词:

编者按:4月28日,肿瘤与精准医疗研讨会在羊城广州成功召开。会议由广东省明医医疗慈善基金会、香港再生医学协会、香港再生医学会、AME出版社和AME 旗下英文期刊 Translational Cancer Research 杂志共同主办,麦迪舜医疗集团、深圳市益康泰来科技有限公司承办,亚太精准医学会和世界医学科学学院协办。国内外最权威的肿瘤专家云集一堂,共同探讨癌症治疗与精准医疗的现状和发展趋势。此次会议中,我们有幸邀请到日本圣路加国际医院免疫与细胞治疗主任 Yuji Heike 接受采访,分享他关于免疫与细胞治疗的经验与心得。

图1. Prof. Heike(右)与 AME 编辑(左)合照

采访中,Heike 教授强调,Anti PD-1 Antibody 是免疫治疗领域的一大突破。在过去,肿瘤医生常常选择化疗作为治疗方法,但是剂量的难以控制一直是难题。近年来,随着 Anti PD-1 Antibody 的研发与应用,肿瘤医生越来越多地倾向于使用该抗体,成效显著。与此同时,Heike教授指出,在未来的一段时间内,Anti PD-1 Antibody 仍会是癌症治疗与免疫治疗的热点。但是它的治疗效果不是完美的,它并非对所有病人都能起作用,因为病人对 Anti PD-1 免疫疗法有不同的应答情况。Heike 教授认为,应该利用生物标记的方法区分不同的病人,再针对性地采取治疗措施。而这不是一朝一夕可以做好的,需要慢慢研究摸索。

更多详情,请猛戳下面采访视频。

采访问题:

  1. Why did you study immunotherapy and cell therapy? Is there any particular reason?

  2. What do you think is the biggest change or success in the field of immunotherapy in recent years?

  3. Recently you published a new study on a new vaccine for acute myeloid leukeima. Can you tell us its differences from previous vaccines and its advantages?

  4. In the future, what areas of research within cancer therapy and immunotherapy do you think are most promising?

专家介绍:

Yuji Heike

St. Luke’s International University,

St, Luke’s International Hospital,

Tokyo, Japan

Prof. Yuji Heike, MD, PhD, is the Chief of Immunotherapy and Cell Therapy Service at St. Luke’s International University, and the Chief of the Laboratory for Joint Research and Development of St. Luke’s International University. He also serves as the Unit Head of Immunotherapy Research Field, Translational Research Group, and Translational Medicine Department, Phase 1 Group, Exploratory Oncology Research & Clinical Trial Center National Cancer Center.

Prof. Heike studies immunotherapy including cancer vaccine, cellular therapy, gene therapy and antibodies. His clinical expertise also covers laboratory medicine especially for immunomonitoring.

科学编辑:李肖梅,AME Publishing Company.

视频编辑:麦雪芳,AME Publishing Company.

comments powered by Disqus

附件